Increased serum C-reactive protein and decreased urinary aquaporin 2 levels are predictive of the efficacy of tolvaptan in patients with liver cirrhosis.
Masato NakaiKoji OgawaRei TakedaMasatsugu OharaNaoki KawagishiTakaaki IzumiMachiko UmemuraJun ItoTakuya ShoGoki SudaKenichi MorikawaNaoya SakamotoPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2017)
Tolvaptan provides a rapid and strong effect to improve water retention in patients with LC. Baseline serum sCD14 and CRP levels are useful predictors of a response to TVP, with a decrease in urinary AQP2 during treatment indicating an early response.